drugset
drugset / Trial / NCT01511510

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

NCT01511510 ↗

Phase 1 Completed 39 enrolled Biogen
RandomizedParallel-groupDouble-blindBasic science

Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.

Timeline

Start
2011-06
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.05 mg Oral
Subject PESAMPATOR Small molecule 0.1 mg Oral
Subject PESAMPATOR Small molecule 0.15 mg Oral
Subject PESAMPATOR Small molecule 0.25 mg Oral

Indications

schizophrenia